OptimizeRx Sets Third Quarter 2018 Conference Call for Monday, November 5, 2018 at 4:30 p.m. ET
23 Oktober 2018 - 2:31PM
OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital
health messaging for the pharmaceutical industry, will hold a
conference call on Monday, November 5, 2018 at 4:30 p.m. Eastern
time to discuss results for the third quarter ended September 30,
2018. The financial results will be issued in a press release prior
to the call.
OptimizeRx management will host the call, followed by a question
and answer period.
Date: Monday, November 5, 2018Time: 4:30 p.m. Eastern time (1:30
p.m. Pacific time)Toll-free dial-in number:
1-888-221-3881International dial-in number:
1-323-794-2591Conference ID: 1275447
Please call the conference telephone number five minutes prior
to the start time. An operator will register your name and
organization. If you have any difficulty connecting with the
conference call, please contact CMA at 1-949-432-7566.
A replay of the call will be available after 7:30 p.m. Eastern
time on the same day through November 26, 2018, as well as
available for replay via the Investors section of the OptimizeRx
website at www.optimizerx.com.
Toll-free replay number: 1-844-512-2921International replay
number: 1-412-317-6671Replay ID: 1275447
About OptimizeRx OptimizeRx® (NASDAQ: OPRX) is
one of the nation’s leading providers of digital health messaging
via electronic health records (EHRs), providing a direct channel
for pharma companies to communicate with healthcare providers. The
company’s cloud-based solution supports patient adherence to
medications by providing real-time access to financial assistance,
prior authorization, education, and critical clinical information.
The company’s network is comprised of leading EHR platforms like
Allscripts, Amazing Charts and Quest, and provides more than half
of the ambulatory patient market with access to these benefits
within their workflow at the point-of-care. For more information,
follow the company on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements This press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole Brooks, Innsena
Communications(Tel) 860-800-2344nicolebrooks@innsena.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024